In the Clinic While utilization of VOCs in the early detection of esophageal cancer has shown promise, future studies should aim at determining which VOCs would be the most specific in diagnosing GI malignancies.
Recent advances in immunotherapy preceded the approval of programmed cell death 1 (PD-1) inhibitors for the treatment of a variety of cancer types.
Isabel Cunningham, MD, advisory board member for CTA, asks Dr Apperley about how to treat patients with CML that cause specialists particular concern.
Although infrequent, malignancy is a cause of upper gastrointestinal bleeding that should be included on the differential diagnosis.
Researchers confirmed that for most patients with melanoma, entry to an adjuvant systemic therapy trial is a preferable first option.
There are key factors to consider when determining the best treatment strategy for pain in patients with cancer.
The placement of an inferior vena cava filter is understudied in patients with cancer and clear guidelines do not exist.
While lower extremity DVTs are the most common, up to 10% of DVTs can occur in upper extremeties in patients with cancer.
Recent research shows that enoxaparin effectively prevents VTE complications in advanced pancreatic cancer without decreasing efficacy of chemotherapy.
Common gastrointestinal symptoms experienced by patients with cancer can vary widely and determining an underlying malignancy can prove difficult.
Researcher found an improvement in aromatase inhibitor-associated arthralgia in both omega-3 fatty acids and placebo treatment.
New treatment modalities are being developed for patients with pancreatic cancer aimed at improving efficacy as well as limiting toxicity.
ABVD and Stanford V treatment regimens show similar efficacy in patients with Hodgkin lymphoma.
Up to 10 percent of ascites diagnoses are related to cancer.
As newer treatment options for peritoneal carcinomatosis are developed, more clinical data is needed to support use in patients with colorectal cancer.
Load More
